Paul Burke - Aion Therapeutic Pres Pharmaceuticals
| ANTCF Stock | USD 0.03 0.02 185.71% |
Insider
Paul Burke is Pres Pharmaceuticals of Aion Therapeutic
| Phone | 416 460 3000 |
| Web | https://www.aiontherapeutic.com |
Aion Therapeutic Management Efficiency
The company has return on total asset (ROA) of (0.9607) % which means that it has lost $0.9607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.1726) %, meaning that it generated substantial loss on money invested by shareholders. Aion Therapeutic's management efficiency ratios could be used to measure how well Aion Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | INSIDER Age | ||
| Mximo Juda | Genomma Lab Internacional | N/A | |
| Alejandro Patio | Genomma Lab Internacional | N/A | |
| Efran Crdova | Genomma Lab Internacional | N/A | |
| Marianne Velasco | Genomma Lab Internacional | N/A | |
| Daniel Neria | Genomma Lab Internacional | N/A | |
| L Porres | Genomma Lab Internacional | N/A | |
| Engineer Galland | Genomma Lab Internacional | N/A | |
| Jorge Valderrama | Genomma Lab Internacional | N/A | |
| Juan Sparvieri | Genomma Lab Internacional | N/A | |
Management Performance
| Return On Equity | -4.17 | |||
| Return On Asset | -0.96 |
Aion Therapeutic Leadership Team
Elected by the shareholders, the Aion Therapeutic's board of directors comprises two types of representatives: Aion Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aion. The board's role is to monitor Aion Therapeutic's management team and ensure that shareholders' interests are well served. Aion Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aion Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patricia Purdy, Co Sec | ||
| Graham Simmonds, COO CEO | ||
| FACS FAANS, Medical Director | ||
| Paul Burke, Pres Pharmaceuticals |
Aion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Aion Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.17 | |||
| Return On Asset | -0.96 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 147.3 M | |||
| Shares Owned By Insiders | 17.68 % | |||
| Price To Book | 5.77 X | |||
| Gross Profit | (1.5 K) | |||
| EBITDA | (3.68 M) | |||
| Net Income | (3.82 M) | |||
| Cash And Equivalents | 1.85 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Aion Pink Sheet
Aion Therapeutic financial ratios help investors to determine whether Aion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aion with respect to the benefits of owning Aion Therapeutic security.